Clinical trials: sponsored by Fujian Cancer Hospital
Gastric Adenocarcinoma
Apatinib Combined With POF for Second-line Treatment of Gastric Adenocarcinoma
In previous studies,the investigators found that POF (A combination of oxaliplatin, fluorouracil and Paclitaxel) regimen appears to be of good efficacy and is well tolerated in patients with advanced gastric cancer.
- Trial name
- NCT03788174
- Testing
- Apatinib, POF
- Where
- 2 sites in China
- Volunteers
- 26 people
- Sponsor
- Fujian Cancer Hospital
Anesthesia, Cervical Cancer
Effects of Anesthesia on Tumor Immunity and Insulin Resistance During Perioperative Period
To evaluate the effects of preoperative oral carbohydrate on postoperative insulin resistance and tumor immunity in cervical cancer patients with neoadjuvant chemotherapy.
- Conditions
- Anesthesia, Cervical Cancer, Carbohydrate, Tumor Immunity
- Trial name
- NCT03872635
- Testing
- oral carbohydrate liquid
- Where
- 2 sites in China
- Volunteers
- 80 people
- Sponsor
- Fujian Cancer Hospital
EGFR Gene Mutation
EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC
A single arm study: EGFR-TKIs Combine With Anlotinib as First-line Treatment in patients with EGFR-mutant non-small-cell lung cancer (NSCLC).
- Trial name
- NCT03720873
- Testing
- erlotinib or gefitinib or icotinib, Anlotinib
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Fujian Cancer Hospital
Malignant Neoplasm of Stomach Stage II
Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer
A single arm study: Apatinib plus paclitaxel as the reverses treatment in advanced gastric cancer which paclitaxel-resistant.
- Trial name
- NCT02697838
- Testing
- Apatinib, Paclitaxel-based chemotherapeutic regimens
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fujian Cancer Hospital
Gastric Adenocarcinoma
Study of the Combination of Apatinib and POF
In previous studies, we found that POF (A combination of oxaliplatin, fluorouracil and Paclitaxel) regimen appears to be of good efficacy and is well tolerated in patients with advanced gastric cancer.
- Trial name
- NCT03707639
- Testing
- Apatinib, POF
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Fujian Cancer Hospital
Recurrent Nasopharyngeal Carcinoma
Nimotuzumab for Recurrent Nasopharyngeal Carcinoma
The study assessed the clinical efficacy, and safety of the combination of Nimotuzumab administered concomitantly with intensity modulated radiation therapy(IMRT) in patients with recurrent nasopharyngeal cancer.
- Trial name
- NCT03666221
- Testing
- Nimotuzumab
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Fujian Cancer Hospital
Cognitive Dysfunction
Cognitive Dysfunction in Patients With Cancer Pain
To investigate the occurrence of cognitive dysfunction in cancer patients with pain in China.Analysis of patients with different cancer pain, different analgesic drugs and different treatments are associated with the severity of…
- Trial name
- NCT03641820
- Where
- China
- Volunteers
- 928 people
- Sponsor
- Fujian Cancer Hospital
Gastrointestinal Cancer
Next-generation Sequencing in Gastrointestinal Cancer
Liquid biopsy has been successfully applied to the treatment and diagnosis of cancer. cfDNA has been paid more and more attention in liquid biopsy.
- Trial name
- NCT03476057
- Testing
- Device： NGS sequencing cfDNA
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fujian Cancer Hospital
Non-squamous Non-small Cell Lung Cancer
Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel
The purpose of this clinical study is to evaluate the tolerability and toxicity of different dose of Anlotinib puls Pemetrexed/Docetaxel in Second-line Treatment of Advanced Gene Negative Non-squamous Non-small Cell Lung Cancer …
- Trial name
- NCT03566576
- Testing
- Anlotinib, Pemetrexed, Docetaxel
- Volunteers
- 18 people
- Sponsor
- Fujian Cancer Hospital
Radiation Induced Oral Mucositis
Appaconitine Patch for Oral Mucositis Pain Caused by Chemoradiotherapy in Patients With Nasopharyngeal Cancer
The purpose of this clinical study is to evaluate the efficacy of lappaconitine adhesive patch in alleviation radiation induced mucositis pain and the improvements in QOL of patients with nasopharyngeal carcinoma .
- Trial name
- NCT03518489
- Testing
- Lappaconitine Adhesive Patch, standard care
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Fujian Cancer Hospital
Squamous Cell Carcinoma
Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell Carcinoma
As a 2nd generation EGFR-TKI that irreversibly binds to EGFR receptors, afatinib is currently recommended as the standard first-line treatment for EGFR mutation-positive lung cancer, and clinical studies are also being actively…
- Trial name
- NCT03486509
- Testing
- Afatinib
- Volunteers
- 2 people
- Sponsor
- Fujian Cancer Hospital
Lung Adenocarcinoma, EGFR Mutation
Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation
Rationale: Advanced non-small-cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations (del19 or L858R) show an impressive progression-free survival between 9 and 11 months when treated with…
- Trial name
- Geber (NCT03486496)
- Testing
- gefitinib, Berberine
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fujian Cancer Hospital
Metastatic Colorectal Cancer
Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC
A randomized phase II trial of FOLFOXIRI in Combination With GM-CSF and IL-2 (FOLFOXIGIL) Versus FOLFOXIRI as First-line Treatment for Patients With Metastatic Colorectal Cancer.
- Trial name
- NCT03222089
- Testing
- Irinotecan, Oxaliplatin, Levoleucovorin
- Where
- China
- Sponsor
- Fujian Cancer Hospital
Gastric Adenocarcinoma
Phase I Study of the Combination of Apatinib and POF
In previous studies, we found that POF (A combination of oxaliplatin, fluorouracil and Paclitaxel) regimen appears to be of good efficacy and is well tolerated in patients with advanced gastric cancer.
- Trial name
- NCT03244774
- Testing
- Apatinib, POF
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Fujian Cancer Hospital
NSCLC Stage IV, Chemotherapy Effect
EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide
EGFR-TKIs are the standard first-line treatment option for EGFR-mutant NSCLC. After a randomized phase II trial, JO25567 was presented at 2014 ASCO, the synergistic effect of progression-free survival(PFS) could be expected when…
- Trial name
- NCT03341494
- Testing
- Thalidomide
- Where
- 2 sites in China
- Volunteers
- 128 people
- Sponsor
- Fujian Cancer Hospital
SCLC
Next-generation Sequencing of Small Cell Lung Cancer to Identify Susceptibility Gene and to Assess Treatment
Participants will be consented into the study after they are found to meet the study inclusion criteria. The clinical staff will schedule a tissue biopsy and a blood draw for the participant to give NGS(Next-generation…
- Trial name
- NCT03244904
- Volunteers
- 80 people
- Sponsor
- Fujian Cancer Hospital
Advanced Gastric Cancer
Docetaxel and S-1 Combination Therapy as Second-line Treatment for Advanced Gastric Cancer
A single-arm phase II study to evaluate the efficacy and safety of docetaxel plus S-1 (DS) as second-line treatment in patients with AGC.
- Trial name
- NCT03137004
- Testing
- Docetaxel, S-1
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Fujian Cancer Hospital
Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction
mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA
The aim of this study was to compare the efficacy and safety of mFOLFOX, mFOLFIRI and FOLFPTX as first-line treatment in AGC or EGJA.
- Trial name
- NCT03045770
- Testing
- Fluorouracil, Oxaliplatin, Irinotecan
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Fujian Cancer Hospital
Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction
Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA
The purpose of this study is to determine whether apatinib plus irinotecan can improve progression free survival compared with single irinotecan in patients with advanced gastric cancer or adenocarcinoma of esophagogastric…
- Trial name
- NCT03030937
- Testing
- Apatinib, Irinotecan
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Fujian Cancer Hospital
EGFR Gene Mutation
EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC
The aim of this study was to compare the efficacy of EGFR-TKIs(Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors) treatment plus concurrent chemotherapy versus sequential treatment with EGFR-TKIs and chemotherapy in…
- Trial name
- effect (NCT02886195)
- Testing
- pemetrexed, cisplatin, Erlotinib
- Volunteers
- 120 people
- Sponsor
- Fujian Cancer Hospital